Latest On Genfit SA (GNFTF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 04:55 EST | News | Genfit: Major Data Release Before End Of Q2 Of 2023 Could Get Ball Rolling | N/A |  |
| 2022-04-12 06:39 EST | News | Genfit SA's (GNFT) CEO Pascal Prigent on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-04-09 02:07 EST | News | Genfit SA (GNFT) CEO Pascal Prigent on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2021-03-18 07:25 EST | Analyst Rating | The Analyst Target Price has decreased from $11.32 to $11.29. | Neutral | |
| 2021-03-17 18:42 EST | Analyst Rating | The Analyst Target Price has decreased from $11.34 to $11.32. | Neutral | |
| 2021-03-14 06:48 EST | Analyst Rating | The Analyst Target Price has decreased from $11.37 to $11.34. | Neutral | |
| 2021-03-13 05:53 EST | Analyst Rating | The Analyst Target Price has increased from $11.32 to $11.37. | Buy | |
| 2021-03-12 17:41 EST | Analyst Rating | The Analyst Target Price has increased from $11.21 to $11.32. | Buy | |
| 2021-03-12 06:15 EST | Analyst Rating | The Analyst Target Price has increased from $11.18 to $11.21. | Buy | |
| 2021-03-11 05:57 EST | Analyst Rating | The Analyst Target Price has increased from $11.14 to $11.18. | Buy | |
| 2021-03-10 06:33 EST | Analyst Rating | The Analyst Target Price has decreased from $11.21 to $11.14. | Neutral | |
| 2021-03-09 06:04 EST | Analyst Rating | The Analyst Target Price has increased from $11.19 to $11.21. | Buy | |
| 2021-03-07 05:43 EST | Analyst Rating | The Analyst Target Price has decreased from $11.25 to $11.19. | Neutral | |
| 2021-03-06 05:47 EST | Analyst Rating | The Analyst Target Price has decreased from $11.33 to $11.25. | Neutral | |
| 2021-03-05 17:45 EST | Analyst Rating | The Analyst Target Price has increased from $11.25 to $11.33. | Buy | |
| 2021-03-05 09:57 EST | Analyst Rating | The Analyst Target Price has decreased from $11.29 to $11.25. | Neutral | |
| 2021-03-04 17:46 EST | Analyst Rating | The Analyst Target Price has increased from $9.34 to $11.29. | Buy | |
| 2021-03-04 09:56 EST | Analyst Rating | The Analyst Target Price has decreased from $11.25 to $9.34. | Neutral | |
| 2021-03-03 17:49 EST | Analyst Rating | The Analyst Target Price has increased from $9.34 to $11.25. | Buy | |
| 2021-03-03 10:04 EST | Analyst Rating | The Analyst Target Price has decreased from $11.29 to $9.34. | Neutral | |
| 2021-03-02 10:01 EST | Analyst Rating | The Analyst Target Price has increased from $11.27 to $11.29. | Buy | |
| 2021-02-28 05:44 EST | Analyst Rating | The Analyst Target Price has decreased from $11.36 to $11.27. | Neutral | |
| 2021-02-27 05:53 EST | Analyst Rating | The Analyst Target Price has decreased from $11.37 to $11.36. | Neutral | |
| 2021-02-26 22:27 EST | Analyst Rating | The Analyst Target Price has decreased from $11.46 to $11.37. | Neutral | |
| 2021-02-26 09:44 EST | Analyst Rating | The Analyst Target Price has increased from $11.45 to $11.46. | Buy | |
| 2021-02-25 06:47 EST | Analyst Rating | The Analyst Target Price has decreased from $11.46 to $11.45. | Neutral | |
| 2021-02-24 06:33 EST | Analyst Rating | The Analyst Target Price has increased from $11.42 to $11.46. | Buy | |
| 2021-02-22 09:49 EST | Analyst Rating | The Analyst Target Price has increased from $11.41 to $11.42. | Buy | |
| 2021-02-21 05:48 EST | Analyst Rating | The Analyst Target Price has increased from $11.39 to $11.41. | Buy | |
| 2021-02-20 05:48 EST | Analyst Rating | The Analyst Target Price has increased from $11.35 to $11.39. | Buy | |
| 2021-02-19 17:26 EST | Analyst Rating | The Analyst Target Price has increased from $11.29 to $11.35. | Buy | |
| 2021-02-19 06:34 EST | Analyst Rating | The Analyst Target Price has decreased from $11.33 to $11.29. | Neutral | |
| 2021-02-18 06:24 EST | Analyst Rating | The Analyst Target Price has decreased from $11.37 to $11.33. | Neutral | |
| 2021-02-17 17:34 EST | Analyst Rating | The Analyst Target Price has increased from $9.37 to $11.37. | Buy | |
| 2021-02-17 05:59 EST | Analyst Rating | The Analyst Target Price has decreased from $11.36 to $9.37. | Neutral | |
| 2021-02-15 05:56 EST | Analyst Rating | The Analyst Target Price has increased from $11.35 to $11.36. | Buy | |
| 2021-02-14 05:46 EST | Analyst Rating | The Analyst Target Price has decreased from $11.37 to $11.35. | Neutral | |
| 2021-02-13 05:46 EST | Analyst Rating | The Analyst Target Price has increased from $11.35 to $11.37. | Buy | |
| 2021-02-12 05:59 EST | Analyst Rating | The Analyst Target Price has decreased from $14.09 to $11.35. | Neutral | |
| 2021-02-11 17:36 EST | Analyst Rating | The Analyst Target Price has increased from $14.02 to $14.09. | Buy | |
| 2021-02-10 09:49 EST | Analyst Rating | The Analyst Target Price has increased from $14 to $14.02. | Buy | |
| 2021-02-07 05:46 EST | Analyst Rating | The Analyst Target Price has increased from $13.92 to $14. | Buy | |
| 2021-02-06 05:47 EST | Analyst Rating | The Analyst Target Price has decreased from $14 to $13.92. | Neutral | |
| 2021-02-05 17:32 EST | Analyst Rating | The Analyst Target Price has increased from $13.91 to $14. | Buy | |
| 2021-02-05 06:12 EST | Analyst Rating | The Analyst Target Price has increased from $11.56 to $13.91. | Buy | |
| 2021-02-04 05:57 EST | Analyst Rating | The Analyst Target Price has decreased from $13.95 to $11.56. | Neutral | |
| 2021-02-03 05:48 EST | Analyst Rating | The Analyst Target Price has decreased from $14.01 to $13.95. | Neutral | |
| 2021-02-02 06:41 EST | Analyst Rating | The Analyst Target Price has decreased from $14.03 to $14.01. | Neutral | |
| 2021-01-31 05:52 EST | Analyst Rating | The Analyst Target Price has increased from $14.01 to $14.03. | Buy | |
| 2021-01-30 05:52 EST | Analyst Rating | The Analyst Target Price has increased from $13.99 to $14.01. | Buy | |
About Genfit SA (GNFTF):
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.
General
- Name Genfit SA
- Symbol GNFTF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 203
- Last Split Factor1009:1000
- Last Split Date2014-01-09
- Fiscal Year EndDecember
- Web URLhttp://www.genfit.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 5.57
- Price/Book (Most Recent Quarter) 5.63
- Enterprise Value Revenue 5.07
View More
Financials
- Most Recent Quarter 2020-06-30
- Profit Margin -172%
- Return on Assets -14%
- Return on Equity -105%
- Revenue Per Share $0
- Gross Profit 38.98 million
- Quarterly Earnings Growth -0.1%
View More
Highlights
- Market Capitalization 206.53 million
- Analyst Target Price $11.29
- Book Value Per Share $2.62
View More
Share Statistics
- Shares Outstanding 41.84 million
- Shares Float 37.14 million
- % Held by Insiders 659%
- % Held by Institutions 4.75%
View More
Technicals
- Beta 1.18
- 52 Week High $21.5
- 52 Week Low $3.75
- 50 Day Moving Average 5.18
- 200 Day Moving Average 4.93
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Genfit SA (GNFTF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Genfit SA (GNFTF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-03-31 | 2020-06-30 | $N/A | -$0.77 | -$0.67 | -14.4% |
| 2019-12-31 | 2020-03-31 | $N/A | -$0.75 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $N/A | -$0.18 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $4.9 million | -$0.18 | ||
| 2019-03-31 | 2019-06-30 | $4.75 million | -$0.93 | -$0.65 | -43.46% |
| 2018-12-31 | 2019-03-31 | $1.61 million | -$0.92 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $1.64 million | -$0.79 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $2.94 million | -$0.80 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $3.1 million | -$0.69 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $1.03 million | -$0.72 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $1.03 million | -$0.64 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $2.31 million | -$0.63 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $2.31 million | -$0.41 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $1.54 million | -$0.39 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $1.54 million | -$0.39 | $0.00 | |
| 2016-06-30 | 2016-09-30 | -$0.42 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | -$0.27 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | -$0.28 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | -$0.19 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | -$0.19 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | -$0.21 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | -$0.20 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | -$0.20 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | -$0.21 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | -$0.29 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | -$0.30 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | -$0.16 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | -$0.16 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | -$0.28 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | -$0.28 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | -$0.04 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | -$0.04 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | -$0.20 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | -$0.21 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | -$0.23 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | -$0.24 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | -$0.31 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | -$0.30 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | -$0.24 | $0.00 |
Genfit SA (GNFTF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Genfit SA (GNFTF) Chart:
Genfit SA (GNFTF) News:
Below you will find a list of latest news for Genfit SA (GNFTF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Genfit SA (GNFTF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Genfit SA (GNFTF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|